microfluidic device access arraytm ifc (fluidigm)
fluidigm is a verified supplier 
fluidigm manufactures this product 
90
Structured Review
fluidigm
microfluidic device access arraytm ifc
Microfluidic Device Access Arraytm Ifc, supplied by fluidigm, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/access+arraytm+ifc/access+array+microfluidic+system/us12018323-607-15-46
Average 90 stars, based on 1 article reviews
Microfluidic Device Access Arraytm Ifc, supplied by fluidigm, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/access+arraytm+ifc/access+array+microfluidic+system/us12018323-607-15-46
Average 90 stars, based on 1 article reviews
microfluidic device access arraytm ifc - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Amplification:Article Title: Nucleic acid encoding reactions Article Snippet: .. In particular embodiments, the inner or (inner and outer) amplification(s) is/are carried out in a microfluidic device designed to facilitate recovery of amplification products after the amplification reaction has been carried out, such as the Multiplexing:Article Title: High-level multiplex amplification Article Snippet: This method can be used, for example, in a targeted sequencing library preparation method Fluidigm ACCESS ARRAY® system to achieve greater than 15,000-plex per reaction at low cost. .. With “on-chip” barcoding, even more “multiplexing” is possible, because Fluidigm's chips, such as the Transfection:Article Title: Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines Article Snippet: Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S4C: Original Western Blots corresponding to A–C, showing the expression and activation levels of RTK effectors upon the overexpression of KRAS-WT and mutant KRAS in MM cells, following stable transposition with Sleeping Beatuy vectors in OPM2 cells, which were either cultured in full cell culture medium as described in materialand methods (Ø PBS) or kept 40 min in PBS without the addition of FBS (40 min PBS). .. Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S5: Strategy of the two-step fusion-PCR using different primer combinations to generate the fusion-proteins attB-V5-KRAS and EmGFP-KRAS (Table S III), Table S1: Clinical parameters of MM patients with and without KRAS mutations, Table S2: Raw intensities and intensity ratios of Western blot bands as well as fold change expression/activation, corresponding to and Figure S2, Table S3: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to and Figure S3, Table S4: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to A–C and Figure S4A–C, Table S5: Exon specific KRAS-primers to generate the amplicons with the 48-48 Western Blot:Article Title: Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines Article Snippet: Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S4C: Original Western Blots corresponding to A–C, showing the expression and activation levels of RTK effectors upon the overexpression of KRAS-WT and mutant KRAS in MM cells, following stable transposition with Sleeping Beatuy vectors in OPM2 cells, which were either cultured in full cell culture medium as described in materialand methods (Ø PBS) or kept 40 min in PBS without the addition of FBS (40 min PBS). .. Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S5: Strategy of the two-step fusion-PCR using different primer combinations to generate the fusion-proteins attB-V5-KRAS and EmGFP-KRAS (Table S III), Table S1: Clinical parameters of MM patients with and without KRAS mutations, Table S2: Raw intensities and intensity ratios of Western blot bands as well as fold change expression/activation, corresponding to and Figure S2, Table S3: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to and Figure S3, Table S4: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to A–C and Figure S4A–C, Table S5: Exon specific KRAS-primers to generate the amplicons with the 48-48 Expressing:Article Title: Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines Article Snippet: Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S4C: Original Western Blots corresponding to A–C, showing the expression and activation levels of RTK effectors upon the overexpression of KRAS-WT and mutant KRAS in MM cells, following stable transposition with Sleeping Beatuy vectors in OPM2 cells, which were either cultured in full cell culture medium as described in materialand methods (Ø PBS) or kept 40 min in PBS without the addition of FBS (40 min PBS). .. Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S5: Strategy of the two-step fusion-PCR using different primer combinations to generate the fusion-proteins attB-V5-KRAS and EmGFP-KRAS (Table S III), Table S1: Clinical parameters of MM patients with and without KRAS mutations, Table S2: Raw intensities and intensity ratios of Western blot bands as well as fold change expression/activation, corresponding to and Figure S2, Table S3: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to and Figure S3, Table S4: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to A–C and Figure S4A–C, Table S5: Exon specific KRAS-primers to generate the amplicons with the 48-48 Biomarker Discovery:Article Title: Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines Article Snippet: Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S4C: Original Western Blots corresponding to A–C, showing the expression and activation levels of RTK effectors upon the overexpression of KRAS-WT and mutant KRAS in MM cells, following stable transposition with Sleeping Beatuy vectors in OPM2 cells, which were either cultured in full cell culture medium as described in materialand methods (Ø PBS) or kept 40 min in PBS without the addition of FBS (40 min PBS). .. Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S5: Strategy of the two-step fusion-PCR using different primer combinations to generate the fusion-proteins attB-V5-KRAS and EmGFP-KRAS (Table S III), Table S1: Clinical parameters of MM patients with and without KRAS mutations, Table S2: Raw intensities and intensity ratios of Western blot bands as well as fold change expression/activation, corresponding to and Figure S2, Table S3: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to and Figure S3, Table S4: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to A–C and Figure S4A–C, Table S5: Exon specific KRAS-primers to generate the amplicons with the 48-48 Polymerase Chain Reaction:Article Title: Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines Article Snippet: Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S4C: Original Western Blots corresponding to A–C, showing the expression and activation levels of RTK effectors upon the overexpression of KRAS-WT and mutant KRAS in MM cells, following stable transposition with Sleeping Beatuy vectors in OPM2 cells, which were either cultured in full cell culture medium as described in materialand methods (Ø PBS) or kept 40 min in PBS without the addition of FBS (40 min PBS). .. Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S5: Strategy of the two-step fusion-PCR using different primer combinations to generate the fusion-proteins attB-V5-KRAS and EmGFP-KRAS (Table S III), Table S1: Clinical parameters of MM patients with and without KRAS mutations, Table S2: Raw intensities and intensity ratios of Western blot bands as well as fold change expression/activation, corresponding to and Figure S2, Table S3: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to and Figure S3, Table S4: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to A–C and Figure S4A–C, Table S5: Exon specific KRAS-primers to generate the amplicons with the 48-48 Article Title: Nucleic acid encoding reactions Article Snippet: Other reagents were stored at room temperature, including PCR Certified Water (Teknova, PN W330); DNA Suspension Buffer (10 mM Tris HCl, 0.1 mM EDTA, pH8.0) (Teknova, PN T0221); and Agilent DNA 1000 Chips (included in the Agilent DNA 1000 DNA kit) (Agilent). .. The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 Article Title: Nucleic acid encoding reactions Article Snippet: The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 ACCESS ARRAYTM IFC s (Fluidigm); and Control Line Fluid Syringes (Fluidigm, PN 89000020). .. Multiplex PCR on the Article Title: Nucleic acid encoding reactions Article Snippet: Other reagents were stored at room temperature, including PCR Certified Water (Teknova, PN W330); DNA Suspension Buffer (10 mM Tris HCl, 0.1 mM EDTA, pH8.0) (Teknova, PN T0221); and Agilent DNA 1000 Chips (included in the Agilent DNA 1000 DNA kit) (Agilent). .. The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 Article Title: Nucleic acid encoding reactions Article Snippet: The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 ACCESS ARRAYTM IFC s (Fluidigm); and Control Line Fluid Syringes (Fluidigm, PN 89000020). .. Multiplex PCR on the Cloning:Article Title: Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines Article Snippet: Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S4C: Original Western Blots corresponding to A–C, showing the expression and activation levels of RTK effectors upon the overexpression of KRAS-WT and mutant KRAS in MM cells, following stable transposition with Sleeping Beatuy vectors in OPM2 cells, which were either cultured in full cell culture medium as described in materialand methods (Ø PBS) or kept 40 min in PBS without the addition of FBS (40 min PBS). .. Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S5: Strategy of the two-step fusion-PCR using different primer combinations to generate the fusion-proteins attB-V5-KRAS and EmGFP-KRAS (Table S III), Table S1: Clinical parameters of MM patients with and without KRAS mutations, Table S2: Raw intensities and intensity ratios of Western blot bands as well as fold change expression/activation, corresponding to and Figure S2, Table S3: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to and Figure S3, Table S4: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to A–C and Figure S4A–C, Table S5: Exon specific KRAS-primers to generate the amplicons with the 48-48 FACS:Article Title: Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines Article Snippet: Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S4C: Original Western Blots corresponding to A–C, showing the expression and activation levels of RTK effectors upon the overexpression of KRAS-WT and mutant KRAS in MM cells, following stable transposition with Sleeping Beatuy vectors in OPM2 cells, which were either cultured in full cell culture medium as described in materialand methods (Ø PBS) or kept 40 min in PBS without the addition of FBS (40 min PBS). .. Negative: JJN3 or OPM2 cells without the vector pT2-CAG-puro. pT2-CAG-puro: JJN3 or OPM2 cells transfected with the empty vector pT2-CAG-puro, Figure S5: Strategy of the two-step fusion-PCR using different primer combinations to generate the fusion-proteins attB-V5-KRAS and EmGFP-KRAS (Table S III), Table S1: Clinical parameters of MM patients with and without KRAS mutations, Table S2: Raw intensities and intensity ratios of Western blot bands as well as fold change expression/activation, corresponding to and Figure S2, Table S3: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to and Figure S3, Table S4: Raw intensities and intensity ratios of western blot bands as well as fold change expression/activation of proteins, corresponding to A–C and Figure S4A–C, Table S5: Exon specific KRAS-primers to generate the amplicons with the 48-48 Adhesive:Article Title: Nucleic acid encoding reactions Article Snippet: Other reagents were stored at room temperature, including PCR Certified Water (Teknova, PN W330); DNA Suspension Buffer (10 mM Tris HCl, 0.1 mM EDTA, pH8.0) (Teknova, PN T0221); and Agilent DNA 1000 Chips (included in the Agilent DNA 1000 DNA kit) (Agilent). .. The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 Article Title: Nucleic acid encoding reactions Article Snippet: Other reagents were stored at room temperature, including PCR Certified Water (Teknova, PN W330); DNA Suspension Buffer (10 mM Tris HCl, 0.1 mM EDTA, pH8.0) (Teknova, PN T0221); and Agilent DNA 1000 Chips (included in the Agilent DNA 1000 DNA kit) (Agilent). .. The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 Control:Article Title: Nucleic acid encoding reactions Article Snippet: Other reagents were stored at room temperature, including PCR Certified Water (Teknova, PN W330); DNA Suspension Buffer (10 mM Tris HCl, 0.1 mM EDTA, pH8.0) (Teknova, PN T0221); and Agilent DNA 1000 Chips (included in the Agilent DNA 1000 DNA kit) (Agilent). .. The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 Article Title: Nucleic acid encoding reactions Article Snippet: Other reagents were stored at room temperature, including PCR Certified Water (Teknova, PN W330); DNA Suspension Buffer (10 mM Tris HCl, 0.1 mM EDTA, pH8.0) (Teknova, PN T0221); and Agilent DNA 1000 Chips (included in the Agilent DNA 1000 DNA kit) (Agilent). .. The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 Multiplex Assay:Article Title: Nucleic acid encoding reactions Article Snippet: The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 ACCESS ARRAYTM IFC s (Fluidigm); and Control Line Fluid Syringes (Fluidigm, PN 89000020). .. Multiplex PCR on the Article Title: Nucleic acid encoding reactions Article Snippet: The following equipment and consumables were used for this protocol: 1.5 mL or 2 mL microcentrifuge tubes; Microcentrifuge with rotor for 2 mL tubes; Microcentrifuge with rotor for 0.2 mL PCR tube strips; Centrifuge with plate carriers; Agilent 2100 BioAnalyzer (Agilent); 96-Well Reaction Plate; MicroAmp Clear Adhesive Film (Applied Biosystems, PN 4306311); IFC Controller AX (2 quantity, pre- and post-PCR) (Fluidigm); FC1 Cycler (Fluidigm); 48.48 ACCESS ARRAYTM IFC s (Fluidigm); and Control Line Fluid Syringes (Fluidigm, PN 89000020). .. Multiplex PCR on the other:Article Title: High-level multiplex amplification Article Snippet: No. 8,691,509, (which is hereby incorporated by reference in its entirety and specifically for its description of microfluidic devices that permit reaction product recovery and related methods) and sold by |